Avestar Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.43M | Buy |
3,194
+399
| +14% | +$186K | 0.09% | 172 |
|
|
2025
Q4 | $1.27M | Sell |
2,795
-1,077
| -28% | -$464K | 0.08% | 184 |
|
|
2025
Q3 | $1.52M | Sell |
3,872
-239
| -6% | -$99.9K | 0.1% | 158 |
|
|
2025
Q2 | $1.83M | Buy |
4,111
+253
| +7% | +$117K | 0.13% | 125 |
|
|
2025
Q1 | $1.87M | Buy |
3,858
+184
| +5% | +$85.7K | 0.16% | 110 |
|
|
2024
Q4 | $1.48M | Buy |
3,674
+518
| +16% | +$240K | 0.13% | 131 |
|
|
2024
Q3 | $1.47M | Buy |
3,156
+104
| +3% | +$50K | 0.15% | 115 |
|
|
2024
Q2 | $1.43M | Buy |
3,052
+148
| +5% | +$64.2K | 0.15% | 118 |
|
|
2024
Q1 | $1.21M | Buy |
2,904
+694
| +31% | +$293K | 0.13% | 136 |
|
|
2023
Q4 | $899K | Buy |
2,210
+237
| +12% | +$87.6K | 0.1% | 131 |
|
|
2023
Q3 | $686K | Buy |
1,973
+23
| +1% | +$8.04K | 0.1% | 133 |
|
|
2023
Q2 | $686K | Sell |
1,950
-1
| -0.1% | -$337 | 0.11% | 113 |
|
|
2023
Q1 | $615K | Buy |
1,951
+629
| +48% | +$189K | 0.11% | 123 |
|
|
2022
Q4 | $382K | Sell |
1,322
-63
| -5% | -$19.2K | 0.07% | 168 |
|
|
2022
Q3 | $401K | Sell |
1,385
-319
| -19% | -$91.8K | 0.1% | 149 |
|
|
2022
Q2 | $480K | Sell |
1,704
-4,711
| -73% | -$1.26M | 0.12% | 125 |
|
|
2022
Q1 | $1.67M | Buy |
6,415
+4,886
| +320% | +$1.16M | 0.27% | 78 |
|
|
2021
Q4 | $336K | Sell |
1,529
-98
| -6% | -$19.1K | 0.04% | 326 |
|
|
2021
Q3 | $295K | Buy |
1,627
+128
| +9% | +$25K | 0.04% | 351 |
|
|
2021
Q2 | $302K | Buy |
1,499
+207
| +16% | +$43.3K | 0.04% | 326 |
|
|
2021
Q1 | $276K | Buy |
1,292
+92
| +8% | +$20.2K | 0.06% | 261 |
|
|
2020
Q4 | $284K | Buy |
1,200
+187
| +18% | +$42.9K | 0.08% | 223 |
|
|
2020
Q3 | $210K | Buy |
1,013
+220
| +28% | +$60.7K | 0.07% | 209 |
|
|
2020
Q2 | $230K | Buy |
+793
| New | +$215K | 0.1% | 159 |
|
|
2019
Q3 | – | Sell |
-674
| Closed | -$107K | – | 822 |
|
|
2019
Q2 | $107K | Buy |
674
+114
| +20% | +$19.9K | 0.07% | 181 |
|
|
2019
Q1 | $86K | Sell |
560
-50
| -8% | -$9.23K | 0.06% | 212 |
|
|
2018
Q4 | $75K | Sell |
610
-55
| -8% | -$9.53K | 0.05% | 215 |
|
|
2018
Q3 | $107K | Buy |
665
+38
| +6% | +$6.77K | 0.06% | 190 |
|
|
2018
Q2 | $91K | Buy |
627
+153
| +32% | +$23.7K | 0.06% | 207 |
|
|
2018
Q1 | $57K | Buy |
474
+63
| +15% | +$10.3K | 0.04% | 236 |
|
|
2017
Q4 | $45K | Buy |
+411
| New | +$60.9K | 0.03% | 263 |
|
Other funds holding VRTX
VCM
VPM
Avestar Capital's VRTX Position: Q1 2026 in Review
Avestar Capital increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, buying an estimated $186K and bringing the position to 3,194 shares worth $1.43M. The position accounts for 0.09% of the portfolio, ranked #172.
Avestar Capital first reported a position in VRTX in Q4 2017 and has held it in 31 quarters since. The position peaked at $1.87M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Avestar Capital held 3,194 shares of Vertex Pharmaceuticals worth $1.43M as of Q1 2026.
- Avestar Capital bought 399 Vertex Pharmaceuticals shares in Q1 2026, an estimated $186K.
- Vertex Pharmaceuticals made up 0.09% of Avestar Capital's portfolio in Q1 2026, its #172 holding.
- Avestar Capital first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
- Avestar Capital's Vertex Pharmaceuticals position peaked at $1.87M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Avestar Capital's 13F filing for Q1 2026, filed 13 May 2026.